SEC Comment Letter for Vaxcyte, Inc. (PCVX) (CIK 0001649094) (PCVX) — Mar 27, 2020
Vaxcyte, Inc. (PCVX) (CIK 0001649094)
Date: March 27, 2020 · CIK: 0001649094 · Accession: 0000000000-20-002681
AI Filing Summary & Sentiment
Letter
March 27, 2020 Grant E. Pickering President and Chief Executive Officer SutroVax, Inc. 353 Hatch Drive Foster City, California 94404 Re:SutroVax, Inc. Amendment No. 3 to Draft Registration Statement on Form S-1 Submitted March 13, 2020 CIK No. 0001649094 Dear Mr. Pickering: We have reviewed your amended draft registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by providing the requested information and either submitting an amended draft registration statement or publicly filing your registration statement on EDGAR. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing the information you provide in response to these comments and your amended draft registration statement or filed registration statement, we may have additional comments. Amendment No. 3 to Draft Registration Statement on Form S-1 Prospectus Summary, page 1 1.We note your revised disclosure in response to our prior comment 1. Please remove your statements here and elsewhere in the prospectus that you believe that SVX-24, if approved, has the potential to become the most broad-spectrum pneumococcal conjugate vaccine addressing the $7 billion global pneumococcal vaccine market. Please also revise your statements here and elsewhere in the prospectus that you believe that you are developing potentially "best-in-class" vaccines. This language implies that your product candidates will be effective and will be better than competing vaccines, neither of which is appropriate at this stage of development.
FirstName LastNameGrant E. Pickering Comapany NameSutroVax, Inc. March 27, 2020 Page 2 FirstName LastName Grant E. Pickering SutroVax, Inc. March 27, 2020 Page 2 You may contact Michael Fay at 202-551-3812 or Al Pavot at 202-551-3738 if you have questions regarding comments on the financial statements and related matters. Please contact Ada D. Sarmento at 202-551-3798 or Celeste Murphy at 202-551-3257 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Robert W. Phillips, Esq.
Show Raw Text
March 27, 2020
Grant E. Pickering
President and Chief Executive Officer
SutroVax, Inc.
353 Hatch Drive
Foster City, California 94404
Re:SutroVax, Inc.
Amendment No. 3 to Draft Registration Statement on Form S-1
Submitted March 13, 2020
CIK No. 0001649094
Dear Mr. Pickering:
We have reviewed your amended draft registration statement and have the following
comments. In some of our comments, we may ask you to provide us with information so we
may better understand your disclosure.
Please respond to this letter by providing the requested information and either submitting
an amended draft registration statement or publicly filing your registration statement on
EDGAR. If you do not believe our comments apply to your facts and circumstances or do not
believe an amendment is appropriate, please tell us why in your response.
After reviewing the information you provide in response to these comments and your
amended draft registration statement or filed registration statement, we may have additional
comments.
Amendment No. 3 to Draft Registration Statement on Form S-1
Prospectus Summary, page 1
1.We note your revised disclosure in response to our prior comment 1. Please remove your
statements here and elsewhere in the prospectus that you believe that SVX-24, if
approved, has the potential to become the most broad-spectrum pneumococcal conjugate
vaccine addressing the $7 billion global pneumococcal vaccine market. Please also revise
your statements here and elsewhere in the prospectus that you believe that you
are developing potentially "best-in-class" vaccines. This language implies that your
product candidates will be effective and will be better than competing vaccines, neither of
which is appropriate at this stage of development.
FirstName LastNameGrant E. Pickering
Comapany NameSutroVax, Inc.
March 27, 2020 Page 2
FirstName LastName
Grant E. Pickering
SutroVax, Inc.
March 27, 2020
Page 2
You may contact Michael Fay at 202-551-3812 or Al Pavot at 202-551-3738 if you have
questions regarding comments on the financial statements and related matters. Please contact
Ada D. Sarmento at 202-551-3798 or Celeste Murphy at 202-551-3257 with any other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Robert W. Phillips, Esq.